Peptide Modifications
Explained

What are peptide modifications?

Peptide modifications are chemical changes to a peptide beyond its plain amino acid chain: a cap on either end, a mirror-image residue, a ring, a fatty acid, an albumin-binding group, a polymer or, non-covalently, a different counter-ion.

Most aim at one problem: short plasma half-lives, commonly due to fast renal clearance and enzymatic degradation, which modification can prolong (Werle and Bernkop-Schnürch, 2006). Each covalent change also alters the formula, mass or stereochemistry, which is how it shows up in identity data. This page covers the chemistry for laboratory research. Nothing on this page is guidance for use in people.

Why native peptides are cleared and degraded quickly

Peptidases are the first route. Exopeptidases trim residues from a free end, aminopeptidases from the N-terminus and carboxypeptidases from the C-terminus, while endopeptidases cut inside the chain. The nine-residue peptide MART-1(27-35) had a calculated half-life of 22 seconds in fresh human plasma, lost to peptidases (Brinckerhoff et al., 1999). Selank and Semax, heptapeptides with free termini, show the fragment pattern: labeled Selank broke down in plasma mainly to TKPRP, TKP, RP and GP, and Semax with nerve cells mainly to HFPGP and PGP (Zolotarev et al., 2006).

Renal filtration is the second route: the kidney filters small molecules out of blood while largely holding back large plasma proteins. The strategies below protect vulnerable bonds, make the molecule bigger, or both.

C-terminal amidation and N-terminal acetylation

Capping is the smallest of the peptide stability modifications. C-terminal amidation turns the terminal carboxylic acid into an amide (-COOH to -CONH2), and N-terminal acetylation puts an acetyl group on the terminal amine. At neutral pH a free C-terminus is negatively charged and a free N-terminus positively charged, so each cap removes a charge, along with the free end that exopeptidases act on. In the MART-1(27-35) study, amidation, acetylation or both markedly prolonged stability in human plasma, and T cells still recognized the capped peptides (Brinckerhoff et al., 1999).

Published examples show each cap. Both CJC-1295 forms end in an amide in PubChem: argininamide without the drug affinity complex and lysinamide with it (CIDs 56841945 and 91971820). In material sold as TB-500, a doping-control laboratory identified Ac-LKKTETQ, residues 17 to 23 of thymosin beta-4 with an acetylated N-terminus, and confirmed it by synthesis (Esposito et al., 2012). PubChem lists it at 889.0 g/mol against 847.0 g/mol for unacetylated LKKTETQ (CIDs 62707662 and 10169788), a C2H2O gain of 42.04 g/mol. Adalank (NA-Selank Amidate) is named for both caps on the Selank sequence.

D-amino acid substitution and unnatural residues

Proteases are built for L-amino acids, so swapping in a mirror-image D residue can make nearby bonds hard to cut. In an 11-residue MUC2 epitope peptide, up to two D residues in the N-terminal flank and three in the C-terminal flank kept antibody recognition and gave high resistance to proteolysis in diluted human serum and a lysosomal preparation (Tugyi et al., 2005).

Shortening somatostatin and replacing L- with D-amino acids gave octreotide, with a plasma half-life of 1.5 hours against a few minutes for somatostatin (Werle and Bernkop-Schnürch, 2006). Non-protein residues, such as N-methylated amino acids, follow the same logic.

The CJC-1295 backbone pairs a D-amino acid with ordinary residue swaps: D-alanine at position 2, where plasma dipeptidyl peptidase cleavage starts, plus glutamine for a deamidation-prone asparagine at 8, alanine for glycine at 15 and leucine for an oxidation-prone methionine at 27 (see the CJC-1295 DAC vs No DAC comparison). A D-for-L swap leaves formula and mass unchanged, so mass spectrometry alone cannot see it.

Peptide cyclization and stapling

Peptide cyclization closes a ring between the two ends, two side chains, or an end and a side chain, through an amide (lactam) or a disulfide bond, limiting the shapes the chain can adopt. A disulfide-cyclized RGD peptide, Ac-Cys-Arg-Gly-Asp-Phe-Pen-NH2, was about 30-fold more stable in solution than linear Arg-Gly-Asp-Phe-OH at pH 7 and 50°C; above pH 8 its stability fell sharply as the disulfide degraded (Bogdanowich-Knipp et al., 1999). That was chemical, not enzymatic, breakdown.

Stapling is a cyclization that locks a helix: a hydrocarbon bridge joins two residues on one face of an alpha helix. Stapled BH3 peptides from the BCL-2 family proved helical, protease-resistant and cell-permeable, and bound their targets with increased affinity (Walensky et al., 2004).

Lipidation, albumin binding and the Drug Affinity Complex

Albumin is a large plasma transport protein, and binding to it is a common route to peptide half-life extension. Lipidation attaches a fatty acid that binds albumin non-covalently: insulins acylated at LysB29 with saturated fatty acids of 10 to 16 carbons bound human albumin with association constants of about 10⁴ to 10⁵ M⁻¹, and differences in affinity were reflected in the timing of the insulin effect in rabbits (Kurtzhals et al., 1995).

The Drug Affinity Complex (DAC) binds covalently. CJC-1295 adds a lysine carrying a maleimidopropionamide group at the C-terminus, and the maleimide bonds to the free thiol on Cys34 of serum albumin. Albumin conjugates of this design resisted dipeptidyl peptidase IV in vitro; in rats, CJC-1295 was present in plasma beyond 72 hours, and its immunoreactivity appeared at the albumin band of a western blot from 15 minutes (Jetté et al., 2005).

In placebo-controlled trials in healthy adults, its estimated half-life was 5.8 to 8.1 days (Teichman et al., 2006). The group adds C13H17N3O4, about 279 g/mol (about 3647 against 3367.9 g/mol). Maleimides also react with other thiols and hydrolyze in water, so thiol additives interfere in stock solutions.

Peptide PEGylation

PEGylation attaches polyethylene glycol (PEG), a flexible, water-soluble polymer, and its main lever is size. In mice, the terminal half-life of PEG in circulation rose from 18 minutes to 1 day as molecular weight rose from 6,000 to 190,000 g/mol, while urinary clearance fell (Yamaoka et al., 1994). A review reported a 330-fold longer plasma half-life for an interferon alpha conjugate with a two-armed 40,000 g/mol PEG than for the native protein (Werle and Bernkop-Schnürch, 2006).

Immunogenicity is the main caveat. Anti-PEG antibodies have been associated with reduced efficacy of, and reactions to, PEG-modified medicines, and one group detected them in about 72% of contemporary samples from the general population, mostly at low levels, and in about 56% of samples from 1970 to 1999 (Yang et al., 2016).

PEG-MGF shows the identity side. PEG size and attachment site vary between preparations, the conjugate has no single formula, and PubChem has no compound record for it; the unconjugated 24-residue peptide is 2868.17 g/mol in the FDA substance registry. A 2026 review notes that PEGylation fundamentally alters pharmacokinetics and tissue exposure, so native-peptide findings cannot be assumed for the conjugate, and lists no reported half-life for PEG-MGF (Dominikowski et al., 2026).

Salt forms: a non-covalent difference

A salt form changes what is in the vial, not the peptide's structure. Basic residues and a free N-terminus pair with counter-ions such as acetate, chloride or trifluoroacetate (TFA), adding mass to the powder but not to the peptide's formula.

HPLC-purified peptides are often TFA salts, and TFA at 10⁻⁸ to 10⁻⁷ M reduced cell numbers in fetal rat osteoblast cultures after 24 hours, while TFA salts of amylin and calcitonin consistently gave less proliferation than hydrochloride salts (Cornish et al., 1999). PubChem lists Selank at 751.9 g/mol and Selank diacetate at 872.0, and Semax at 813.9 and Semax acetate at 874.0. On a certificate, the counter-ion lowers peptide content without changing identity.

Peptide stability modifications at a glance

Identity testing compares a measured mass with one calculated from the full structure, so every cap, ring and added group belongs in that calculation. What is a COA? and how to choose a peptide supplier cover what a certificate should show. In sport, the 2026 WADA Prohibited List names CJC-1295 under S2.2.4, and mechano growth factors and TB-500 under S2.3; S2 substances are prohibited at all times.

Key sources

1. Brinckerhoff LH, et al. "Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines." Int J Cancer. 1999. PMID 10495424.
2. Jetté L, et al. "Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog." Endocrinology. 2005. PMID 15817669. DOI 10.1210/en.2004-1286.
3. Yang Q, et al. "Analysis of Pre-existing IgG and IgM Antibodies against Polyethylene Glycol (PEG) in the General Population." Anal Chem. 2016. PMID 27804292. DOI 10.1021/acs.analchem.6b03437.

Frequently asked questions

What are peptide modifications?

Chemical changes to a peptide's ends, residues, shape or size, mostly designed to slow peptidase breakdown or renal clearance (Werle and Bernkop-Schnürch, 2006).

What does C-terminal amidation do?

It turns the terminal acid into an amide, removing a negative charge and 0.98 g/mol. Alone or with N-terminal acetylation, it markedly prolonged a peptide's stability in human plasma (Brinckerhoff et al., 1999).

What is N-terminal acetylation?

An acetyl group on the terminal amine, which removes its positive charge and adds 42.04 g/mol. In material sold as TB-500, a doping-control laboratory identified the acetylated fragment Ac-LKKTETQ (Esposito et al., 2012).

What is a drug affinity complex?

A maleimide group on a lysine added at the C-terminus of CJC-1295, which bonds covalently to the Cys34 thiol of serum albumin (Jetté et al., 2005).

What is peptide PEGylation?

Attaching polyethylene glycol to make a peptide larger. In mice, larger PEG stayed in circulation longer and was cleared less in urine (Yamaoka et al., 1994); anti-PEG antibodies are the main caveat.

Does a D-amino acid change the molecular weight?

No. Formula and mass stay the same, so mass spectrometry alone cannot detect the swap, yet resistance to proteases can change sharply (Tugyi et al., 2005).

Related guides

• What is a peptide?
• CJC-1295 DAC vs No DAC comparison
• PEG-MGF research guide
• TB-500 vs thymosin beta-4 comparison
• Selank and Semax research guides
• What is a COA?
• How to choose a peptide supplier
• TFA vs acetate peptide salts
• How research peptides are made
• COA portal: published certificates, by lot
• Amino acid codes and residue masses
• Research hub

Disguised Alpha products are for research use only. They have not been evaluated for safety or effectiveness in humans. Not for human consumption. All products are intended for laboratory research purposes only.